ANTHONY CAPOBIANCO: Open Payments
NPI 1659352482 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,150 in 108 payments from 14 companies in 2025. Trend: 2023 $1,244 · 2024 $1,694 · 2025 $2,150
Food & beverage: $2,150
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $831 |
| Gilead Sciences, Inc. | 28 | $420 |
| Madrigal Pharmaceuticals | 14 | $244 |
| Ardelyx, Inc. | 7 | $166 |
| Ipsen Biopharmaceuticals, Inc | 7 | $145 |
| Janssen Biotech, Inc. | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Intercept Pharmaceuticals, Inc. | 1 | $26 |
Products named: LINZESS, REZDIFFRA, IBSRELA, IQIRVO, CREON, TREMFYA, VIBERZI, ENTYVIO.
Industry payments across CT — which companies pay providers there.
